QURE

uniQure N.V. NASDAQ

Healthcare ·Biotechnology ·NL · uniqure.com

$19.13

Mkt Cap $1.1B

52w Low $8.73 16.6% of range 52w High $71.50

50d MA $16.96 200d MA $25.40

P/E (TTM) -5.5x

EV/EBITDA -10.3x

P/B 5.5x

Debt/Equity 2.7x

ROE -100.0%

P/FCF -7.7x

RSI (14) —

ATR (14) —

Beta 0.75

50d MA $16.96

200d MA $25.40

Avg Volume 3.2M

About

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment …

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Mar 2, 2026	AMC	-0.93	-0.56	+39.8%	10.50	-12.7%	-14.0%	-13.9%	+1.4%	+35.9%	+71.3%	+60.9%	—
Nov 10, 2025	AMC	-0.85	-1.38	-62.4%	26.15	+1.3%	+17.9%	+15.2%	+16.0%	+14.3%	+16.0%	-23.0%	—
Jul 29, 2025	AMC	-0.89	-0.69	+22.5%	13.68	+8.6%	+5.7%	+1.8%	+0.1%	+0.7%	+2.3%	+18.9%	—
May 9, 2025	AMC	-1.07	-0.82	+23.4%	12.79	-0.2%	+2.8%	+0.2%	-1.1%	+3.6%	+7.1%	+32.1%	—
Feb 27, 2025	AMC	-0.60	-1.50	-150.0%	12.07	-5.1%	+8.9%	-9.7%	-6.1%	+0.2%	+3.6%	-12.2%	—
Nov 5, 2024	AMC	-1.12	-0.91	+18.8%	6.06	+1.5%	+18.2%	+22.6%	+28.5%	+26.4%	+11.1%	+8.7%	—
Aug 1, 2024	AMC	-1.24	-1.16	+6.5%	7.48	-0.7%	-2.3%	+1.3%	+1.1%	-4.8%	-3.3%	-25.5%	—
May 7, 2024	AMC	-1.31	-1.36	-3.8%	4.82	-1.5%	+1.5%	+5.2%	+2.1%	+1.2%	+1.9%	+10.2%	—
Feb 28, 2024	AMC	-1.54	-1.53	+0.6%	6.69	-8.5%	-14.1%	-16.4%	-22.9%	-24.7%	-22.6%	-22.1%	—
Nov 7, 2023	AMC	-1.49	-1.88	-26.2%	6.88	+3.1%	-5.4%	-9.2%	-12.0%	-12.9%	-3.8%	+6.0%	—
Aug 1, 2023	AMC	2.97	-1.44	-148.5%	10.62	-2.3%	-5.3%	-9.0%	-11.3%	-16.0%	-19.2%	-18.0%	—
May 9, 2023	AMC	-1.02	-1.63	-59.8%	21.79	+0.9%	+1.9%	+1.7%	+0.4%	-0.6%	-8.2%	-4.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 20	Goldman Sachs	Maintains	Neutral → Neutral	—	$17.58	$17.50	-0.5%	+2.6%	-0.7%	+1.1%	-0.2%	+2.6%
Mar 23	Barclays	Maintains	Equal Weight → Equal Weight	—	$16.09	$16.06	-0.2%	-1.1%	-5.7%	+1.7%	-3.0%	-8.2%
Mar 11	Mizuho	Upgrade	Neutral → Outperform	—	$18.26	$18.51	+1.4%	-3.8%	-7.2%	-15.0%	-12.7%	-14.5%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.99	$17.96	-0.2%	+1.5%	-2.4%	-5.8%	-13.7%	-11.4%
Mar 9	RBC Capital	Upgrade	Sector Perform → Outperform	—	$14.27	$18.02	+26.3%	+26.1%	+28.0%	+23.1%	+18.7%	+8.8%
Mar 9	Chardan Capital	Maintains	Buy → Buy	—	$14.27	$18.02	+26.3%	+26.1%	+28.0%	+23.1%	+18.7%	+8.8%
Mar 9	Wells Fargo	Upgrade	Equal Weight → Overweight	—	$14.27	$18.02	+26.3%	+26.1%	+28.0%	+23.1%	+18.7%	+8.8%
Mar 3	Wells Fargo	Downgrade	Overweight → Equal Weight	—	$10.50	$9.17	-12.7%	-14.0%	-13.9%	+1.4%	+35.9%	+71.3%
Mar 3	Goldman Sachs	Maintains	Neutral → Neutral	—	$10.50	$9.17	-12.7%	-14.0%	-13.9%	+1.4%	+35.9%	+71.3%
Mar 3	Mizuho	Downgrade	Outperform → Neutral	—	$10.50	$9.17	-12.7%	-14.0%	-13.9%	+1.4%	+35.9%	+71.3%
Mar 3	Chardan Capital	Maintains	Buy → Buy	—	$10.50	$9.17	-12.7%	-14.0%	-13.9%	+1.4%	+35.9%	+71.3%
Mar 2	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$15.63	$9.19	-41.2%	-32.8%	-42.2%	-42.2%	-31.9%	-8.7%
Feb 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.05	$25.55	-1.9%	-5.1%	-7.4%	-14.1%	-21.3%	-16.5%
Dec 11	Stifel	Maintains	Buy → Buy	—	$20.14	$20.00	-0.7%	-1.9%	-3.1%	+1.4%	+8.7%	+14.3%
Dec 9	Mizuho	Maintains	Outperform → Outperform	—	$21.77	$21.62	-0.7%	-4.5%	-7.5%	-9.3%	-10.4%	-6.2%
Dec 4	Chardan Capital	Maintains	Buy → Buy	—	$25.48	$21.25	-16.6%	-10.8%	-16.3%	-14.6%	-18.4%	-21.0%
Nov 12	Wells Fargo	Maintains	Overweight → Overweight	—	$30.84	$29.86	-3.2%	-2.3%	-1.6%	-3.1%	-1.7%	-3.7%
Nov 11	Chardan Capital	Maintains	Buy → Buy	—	$26.15	$26.49	+1.3%	+17.9%	+15.2%	+16.0%	+14.3%	+16.0%
Nov 10	Leerink Partners	Maintains	Outperform → Outperform	—	$27.79	$26.50	-4.6%	-5.9%	+11.0%	+8.4%	+9.2%	+7.5%
Nov 4	William Blair	Downgrade	Outperform → Market Perform	—	$34.29	$30.81	-10.1%	-11.2%	-24.0%	-19.8%	-19.0%	-23.7%
Nov 4	Goldman Sachs	Maintains	Neutral → Neutral	—	$34.29	$30.81	-10.1%	-11.2%	-24.0%	-19.8%	-19.0%	-23.7%
Nov 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$34.29	$30.81	-10.1%	-11.2%	-24.0%	-19.8%	-19.0%	-23.7%
Nov 4	RBC Capital	Maintains	Outperform → Outperform	—	$34.29	$30.81	-10.1%	-11.2%	-24.0%	-19.8%	-19.0%	-23.7%
Nov 3	Chardan Capital	Maintains	Buy → Buy	—	$67.69	$23.05	-65.9%	-49.3%	-55.0%	-61.5%	-59.4%	-58.9%
Oct 6	HC Wainwright & Co.	Maintains	Buy → Buy	—	$54.92	$55.55	+1.1%	-3.7%	+5.5%	+9.2%	+15.9%	+12.1%
Oct 2	Wells Fargo	Maintains	Overweight → Overweight	—	$54.99	$55.87	+1.6%	-0.9%	-0.1%	-3.8%	+5.3%	+9.1%
Sep 25	Chardan Capital	Maintains	Buy → Buy	—	$47.50	$50.43	+6.2%	+10.8%	+14.3%	+25.1%	+22.9%	+15.8%
Sep 25	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$47.50	$50.43	+6.2%	+10.8%	+14.3%	+25.1%	+22.9%	+15.8%
Sep 25	Mizuho	Maintains	Outperform → Outperform	—	$47.50	$50.43	+6.2%	+10.8%	+14.3%	+25.1%	+22.9%	+15.8%
Sep 25	Wells Fargo	Maintains	Overweight → Overweight	—	$47.50	$50.43	+6.2%	+10.8%	+14.3%	+25.1%	+22.9%	+15.8%
Sep 25	Guggenheim	Maintains	Buy → Buy	—	$47.50	$50.43	+6.2%	+10.8%	+14.3%	+25.1%	+22.9%	+15.8%
Sep 25	Goldman Sachs	Maintains	Neutral → Neutral	—	$47.50	$50.43	+6.2%	+10.8%	+14.3%	+25.1%	+22.9%	+15.8%
Sep 24	Leerink Partners	Maintains	Outperform → Outperform	—	$13.66	$39.36	+188.1%	+247.7%	+285.4%	+297.6%	+334.8%	+327.3%
Sep 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.66	$39.36	+188.1%	+247.7%	+285.4%	+297.6%	+334.8%	+327.3%
Sep 24	Stifel	Maintains	Buy → Buy	—	$13.66	$39.36	+188.1%	+247.7%	+285.4%	+297.6%	+334.8%	+327.3%
Sep 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.95	$18.16	+1.2%	-2.9%	-2.6%	-2.6%	-5.6%	-8.1%
Sep 8	Chardan Capital	Maintains	Buy → Buy	—	$17.95	$18.16	+1.2%	-2.9%	-2.6%	-2.6%	-5.6%	-8.1%
Sep 5	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.73	$17.92	+1.1%	+1.2%	-1.7%	-1.4%	-1.4%	-4.5%
Aug 29	Chardan Capital	Maintains	Buy → Buy	—	$16.26	$16.27	+0.1%	+0.4%	+4.6%	+6.9%	+9.0%	+10.4%
Jul 29	Chardan Capital	Maintains	Buy → Buy	—	$14.98	$14.74	-1.6%	-8.7%	-3.5%	-7.1%	-8.5%	-8.1%
May 30	Chardan Capital	Maintains	Buy → Buy	—	$14.90	$14.77	-0.9%	-2.9%	-2.8%	+1.7%	+0.4%	+11.5%
May 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.04	$15.90	+5.7%	-0.9%	-3.8%	-3.7%	+0.8%	-0.5%
May 12	Chardan Capital	Maintains	Buy → Buy	—	$12.79	$12.76	-0.2%	+2.8%	+0.2%	-1.1%	+3.6%	+7.1%
May 12	Guggenheim	Maintains	Buy → Buy	—	$12.79	$12.76	-0.2%	+2.8%	+0.2%	-1.1%	+3.6%	+7.1%
May 6	Chardan Capital	Maintains	Buy → Buy	—	$15.89	$15.51	-2.4%	-27.8%	-36.7%	-22.9%	-19.5%	-17.2%
Apr 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$13.00	$12.94	-0.5%	+2.2%	+10.7%	+10.7%	+9.7%	+9.1%
Apr 1	Chardan Capital	Maintains	Buy → Buy	—	$10.60	$10.77	+1.6%	-6.5%	+0.2%	-8.0%	-15.5%	-17.4%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.90	$10.71	-1.7%	+3.9%	+10.9%	+14.8%	+12.2%	+7.3%
Feb 28	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$12.07	$11.46	-5.1%	+8.9%	-9.7%	-6.1%	+0.2%	+3.6%
Jan 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.67	$15.89	+1.4%	+0.8%	-2.2%	-2.7%	+0.8%	+0.4%

Recent Filings

8-K · 7.01 ! Medium

uniQure N.V. -- 8-K 7.01: Regulation FD Disclosure

uniQure (QURE) disclosed material information via press release to comply with Regulation FD, ensuring equal public access to company announcements without prior selective disclosure to investors.

Apr 30

8-K · 7.01 ! Medium

uniQure N.V. -- 8-K 7.01: Regulation FD Disclosure

uniQure announced a regulatory update on AMT-130, its investigational Huntington's disease gene therapy, potentially signaling progress toward commercialization or addressing previous regulatory concerns.

Mar 2

Data updated apr 26, 2026 9:44pm · Source: massive.com